Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication October 17, 2015
- Accepted for publication December 15, 2015
- Published online July 1, 2016.
Article Versions
- previous version (January 21, 2016 - 05:36).
- previous version (June 9, 2016 - 10:28).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Richard P. Baum*,1,
- Harshad R. Kulkarni*,1,
- Christiane Schuchardt1,
- Aviral Singh1,
- Martina Wirtz2,
- Stefan Wiessalla1,
- Margret Schottelius2,
- Dirk Mueller1,
- Ingo Klette1 and
- Hans-Jürgen Wester2
- 1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
- 2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
- For correspondence or reprints contact: Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. E-mail: richard.baum{at}zentralklinik.de
Statistics from Altmetric.com
Cited By...
Article usage
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Jump to section
Related Articles
Cited By...
- The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
- Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
- First Clinical Results for PSMA-Targeted {alpha}-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
- Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
- 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
- JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
- Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
- A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
- Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
- The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- PSMA Ligands for PET Imaging of Prostate Cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer
- 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
- From NETTER to PETTER: PSMA-Targeted Radioligand Therapy
- Targeted {alpha}-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
- Nuclear Medicine in Cancer Theranostics: Beyond the Target
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
- Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer